List of Devices Companies in Massachusetts - 91

3Daughters is a clinical development company focused on enhancing women’s healthcare through innovative contraceptive solutions. The company aims to fill critical gaps in women's health by developing research-driven products that prioritize patient safety, efficacy, and accessibility. Their flagship products include 3D-001, a frameless, nonhormonal intrauterine device (IUD) designed to reduce insertion pain, and the Slider™ System, which features the i-Slider™ for insertion and the r-Slider™, a magnetic retriever for easy placement and removal. This technology leverages physics and geometry to improve comfort and minimize complications associated with traditional IUDs. 3Daughters targets women seeking reliable, long-acting contraception, particularly those who may be deterred by pain or hormonal side effects. The company has secured over $2 million in seed funding to advance its products through clinical trials, with a commitment to regulatory compliance and quality management. Their mission is to transform women’s healthcare by improving contraceptive accessibility and comfort.

Based in Danvers, Massachusetts, USA, Abiomed, Inc., part of Johnson & Johnson MedTech, is a leading provider of medical technology that provides circulatory support and oxygenation. Our products are designed to enable the heart to rest and recover by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit www.abiomed.com. Important Safety Info: https://bit.ly/39kvb47

Access Vascular is offering our suite of vascular access solutions designed to help clinicians address common catheter complications that afflict patients while helping save hospitals time and money.

Ace Vision Group, Inc. (AVG) is a privately held U.S. ophthalmic medical device company developing Laser Microporation Therapeutic technologies to address age-related eye dysfunction and address the eye's natural biomechanical performance. AVG's Laser Scleral Microporation (LSM) is a therapeutic eye laser treatment that aims to restore visual function naturally without sacrificing distance vision. AVG's brand promise is to provide the field of ophthalmology with innovative devices, Microporation Therapeutic procedures, and education for the treatment of age-related ocular dysfunction, disability, and disease.

Actipulse Neuroscience® is a neurotechnology company focused on non-invasive brain stimulation therapies for neurological and psychiatric disorders. Founded in 2017, the company has offices in Cambridge, MA, and Paris, with a presence in Mexico. Actipulse aims to make neuromodulation treatments accessible by transitioning them from hospitals to home-based solutions, targeting conditions such as depression, Alzheimer’s, and Parkinson’s diseases. The company has developed a proprietary portable transcranial magnetic stimulation (TMS) device designed for home use. This device delivers high-frequency magnetic pulses to address issues like neuroinflammation and neuroplasticity loss. Actipulse is conducting clinical trials for major depressive disorder and exploring applications for neurodegenerative disorders. Their home-based treatment model allows for remote administration of TMS under clinical guidance, integrating with telemedicine platforms. Actipulse envisions establishing neuromodulation as a standard therapy alongside traditional pharmacological treatments.

Advanced Radiation Therapy is the provider of AccuBoost. AccuBoost is the latest innovation in breast radiation therapy. The primary beneficiaries of the AccuBoost Technique are the breast cancer patients: who receive conformal radiation with better targeting, less toxicity, much less skin reaction, minimum exposure to the heart and lungs and a superior cosmetic result.

Alcresta Therapeutics is dedicated to developing and commercializing novel, enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. The company uses its proprietary technology platform to support a broad pipeline of products, with an initial focus on pancreatic insufficiency or fat malabsorption, which results in malabsorption common in cystic fibrosis, digestive cancers, preterm birth, and other serious diseases. The company’s lead product, RELiZORB®, is designed to reliably and efficiently deliver the optimal nutritional and caloric benefit from existing enteral feeding formulas by improving the breakdown and absorption of fats, in particular long-chain polyunsaturated fatty acids like omega-3 (including DHA, EPA). RELiZORB is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula. The company’s platform is supported by our extensive experience in pharmaceutical, medical device and nutritional product development. Based in Massachusetts, the company is backed by top-tier venture investors Athyrium Capital Management, Bessemer Venture Partners, Frazier Healthcare, and Third Rock Ventures.

AVS is an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease. It was founded in 2018 by Hitinder Gurm, M.D., Interventional Cardiologist and Chief Clinical Officer at University of Michigan, and Robert Chisena, Ph.D., Chief Technical Officer at AVS. We are redefining interventional therapy for severely calcified lesions with our Pulse IVL System, which uses a novel pulsatile mechanism of action to shatter calcium and expand narrowed vessels, all with a single device. To learn more about pulsatile intravascular lithotripsy, visit www.avspulse.com.

Arsenal Medical is a clinical-stage company that develops biomaterials to solve challenging and underserved medical problems. It was founded by serial entrepreneur-investor Carmichael Roberts and academic luminaries Robert Langer and George Whitesides, who shared a vision for how materials can transform medicine. The company’s foundational product, ResQFoam, is a life-saving intervention that addresses non-compressible intra-abdominal hemorrhage in trauma patients. It has been designated a breakthrough device by the FDA.

Arxspan provides cloud-based solutions to meet the scientific data management needs of leading life sciences, chemicals, and scientific companies globally. Arxspan offers ArxLab®, a suite of web-based scientific informatics applications, allowing scientists to record, manage, and share their research data​: * Notebook - Intuitive electronic laboratory notebook (ELN) optimized for collaborative models in current research environments * BioReg/ChemReg Registration - Configurable repository for registering unique chemical/biological entities and subsequent batches * Assay - Flexible system for registering assay protocol and result data * Inventory - Comprehensive tool for defining and managing chemical and biological compounds, reagents, equipment, and other items * Search - Robust decision support platform for querying, visualizing, and reporting data * Workflow - ArxLab Workflow allows users to create new work requests and to assign them to users and/or groups. The workflow management tool enables scientists to manage and prioritize all scientific projects, as well as to make procedure requests to internal colleagues and external partners. For more information, please visit our website at www.arxspan.com

Developing seamless neural interfaces.

Beeken Biomedical is an medical device company focused on the development, licensing and commercialization of wound care products. Beeken Biomedical introduces innovative and cost-effective technologies that rapidly stop bleeding and help protect wounds from infection. Beeken Biomedical is committed to improve solutions in wound care for healthcare professionals and consumers.

We provide you with the best experts in the biopharma industry. Through our flexible, consultative approach, we'll align you with professionals with the expertise you need when you need them the most. From early clinical and device development to the post-market phase, we help you bridge your expertise gaps.

BioSurfaces, based in Ashland, Massachusetts, is a life science company with deep leadership and a diverse team of specialists. The company's proprietary electrospinning technology known as Bio-Spun™ creates product solutions by engineering biology with synthetic cellular matrices for applications ranging from IVRT and delivery of bio-active therapeutics to medical devices and consumer health products. These materials can be made to form a variety of unusual and difficult-to-manufacture shapes while also demonstrating improved biocompatibility over other textile-based materials. The BioSurfaces manufacturing process also allows the incorporation of drugs or other bioactive agents directly into the nanofibers for localized release. BioSurfaces' technology is validated by leading organizations in pharmaceuticals, medical devices, life sciences, and consumer products.

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient product for triage and monitoring of disease progression.

We are part of bess group (www.bessgroup.com), a group of dynamic and developing companies, headed by our holding company bess AG (Berlin, Germany). It is our vision to provide life sciences products of high value yet cost-effective, enabling us to become market leaders in as many of our medical fields as possible. Though much has changed at Boston Medical Products over the past 39 years, one thing remains constant: our commitment to deliver the world's finest specialty surgical products - products that clinicians rely on and patients can trust. Founded in 1980 by three physicians - including world-renowned ENT surgeon William W. Montgomery, M.D. - as a way to make Dr. Montgomery's original innovations widely available, Boston Medical Products continues to be driven by his life-long commitment to superior patient care. Over the years since our beginning, we have expanded our line of products with innovations from some of the world's leading physicians, health care innovators, and opinion leaders. Boston Medical Products today develops, manufactures and sells many different types of specialty products that meet the exacting needs of clinicians specializing in Otolaryngology, Pulmonary Medicine, Respiratory Therapy and Speech Pathology. In the established patient oriented tradition, Boston Medical Products has developed an educational website www.trachs.com as a service to provide patients with the very best products and resources for their laryngectomy and tracheostomy needs. It is a website where you can not only find the products you need for your care and comfort, but information and support that will help you make decisions and improve your quality of life.

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions.

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS.

Sebela Pharmaceuticals is a U.S. pharmaceutical company with a market-leading position in Gastroenterology and a focus on innovation in Women's Health. Our Vision is to build the leading Gastroenterology company in the U.S., with a complementary focus on innovation in Women's Health, premised on our expertise in pharmaceutical development and commercialization. We value dedication, energy, and enthusiasm, and we focus on innovation and results while striving to achieve our corporate mission and vision. Sebela Pharmaceuticals is committed to cultivating an inclusive environment where all employees are treated with respect. We accomplish this by fostering a culture of diversity, equity and inclusion, which is essential to innovation and continuous improvement. Sebela operates from three locations with offices in Roswell, Georgia, Braintree, MA and headquarters in Dublin, Ireland.

Brixton Biosciences is a clinical-stage life sciences company developing novel therapies for chronic and acute pain. Their Neural Ice™ has the potential for long-lasting pain control from one injection, intended to eradicate the pain of pain.

CereVasc, Inc. is a clinical-stage, medical device company developing novel treatments for neurological diseases. The company is focused on developing the eShunt™ System for the treatment of patients with hydrocephalus. CereVasc aims to improve patient outcomes and redefine the treatment of communicating hydrocephalus through its innovative medical devices.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and CGT0206 inhibitors. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer’s disease and expects to start pivotal studies in 2022. The company’s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.

Corvia Medical, Inc. is revolutionizing the treatment of heart failure with a novel transcatheter structural heart device. Founded in 2009 and headquartered in Tewksbury, MA, Corvia Medical is dedicated to transforming the standard of care for heart failure treatment, enabling patients to reclaim their lives. The Corvia® Atrial Shunt is the world’s first transcatheter device approved by the European Union to treat heart failure with preserved (HFpEF) or mid-range (HFmrEF) ejection fraction. Privately held, the company is backed by Third Rock Ventures, General Catalyst Partners, AccelMed, and Lumira Ventures, Edward Lifesciences and an undisclosed strategic investor. In the United States, the Corvia Atrial Shunt System is an investigational device and not available for commercial distribution or sale.

Corza Medical's mission is to aid and champion the surgical community with outstanding products and remarkable service that save time, money and effort. We are a leading provider of medical devices and Biosurgery serving surgeons and their teams, distributors and OEM partners around the world. With our expanding platform of industry-leading brands, including Quill® barbed sutures, Sharpoint® and Look™ surgical sutures, Katena® reusable ophthalmic instruments, Sharpoint ophthalmic knives, the TachoSil® fibrin sealant matrix, as well as Pearsalls and FSSB OEM solutions, Corza Medical delivers an exceptional customer experience and outstanding value to the entire surgical community. Find out more at http://corza.com

Cynosure is a leader in the medical devices industry specializing in aesthetic medicine and cosmetic procedures.

Cytrellis Biosystems, Inc. is a medical technology company located in Woburn, Massachusetts, founded in 2012. The company focuses on developing and commercializing innovative aesthetic devices aimed at dermatology and scar reduction. Its mission is to provide non-surgical solutions for sagging skin associated with aging, enhancing skin appearance and restoring youthful beauty. The primary product offered by Cytrellis is the ellacor System, which employs Micro-Coring Technology. This system is designed to treat moderate to severe wrinkles in adults aged 22 and older, specifically targeting the mid to lower face. The ellacor System enables aesthetic practitioners to effectively address age-related skin changes. Cytrellis Biosystems collaborates with leading physicians and partners to implement its aesthetic solutions. With a strong leadership team experienced in medical device development, the company is well-positioned in the beauty and personal care industry, competing with other notable players in the aesthetic and medical device sectors.

Dynocardia is a biomedical device development company committed to satisfying critical unmet needs to improve healthcare worldwide. ViTrack™, our lead diagnostic device, is powered our proprietary technology making it the only stand-alone, cuff-less device that allows for continuous, non-invasive blood pressure (cNIBP) measurement. Unlike conventional occlusive devices, ViTrack offers direct, beat-to-beat measurement of blood pressure that is wrist-wearable, mobile, and easy to use, with the accuracy of intra-arterial lines. ViTrack, with data-rich capability that includes heart rate, heart rhythm, and respiratory parameters in addition to blood pressure, enables early intervention prior to acute events.

At EnClear Therapies, we are combining Bioscience & Med-tech expertise to develop solutions that improve and extend the lives of patients with CNS disease. The team at EnClear is developing systems and medical interventions that Access, Recirculate & Modify CSF for: › Targeted removal of toxicity from CSF correlated to neurodegenerative disease progression. › Continuous localized delivery of therapeutics & monitoring of CSF to ensure effective and personalized therapy.

Encora Therapeutics is a healthcare technology company based in Boston, Massachusetts, founded in 2018. The company focuses on developing innovative, non-invasive wearable solutions for individuals with neurological movement disorders. Their mission is to enhance the quality of life for those affected by these conditions through advanced wearable technology and personalized treatments. The company specializes in wrist-worn vibratory stimulation devices that utilize artificial intelligence-powered vibration therapy. These wearables are designed to provide tremor relief and monitor disease progression, particularly for conditions like essential tremor. Clinical trials have shown significant reductions in tremor severity with their devices, which are user-friendly and well-tolerated. Encora Therapeutics employs advanced technologies such as signal processing and reinforcement learning to create effective solutions tailored to individual patient needs. Their clinical research has received recognition, including an "Abstract of Distinction" at the 2025 American Academy of Neurology Annual Meeting, underscoring the safety and efficacy of their products.

Epicore Biosystems is a digital health company developing advanced sweat-sensing wearables that provide real-time personalized health insights for hydration, stress, and wellness. Our clinically validated products are deployed globally and licensed by leading brands in the sports and fitness, occupational safety, and clinical trials industries.

Exergen Corporation is the recognized world leader in industrial and medical non-invasive temperature technology. From providing temperature sensors for NASA and various industries to creating one of the world's most popular baby gifts, Exergen creates non-invasive temperature measurement devices providing lower cost, higher accuracy, less invasiveness, and greater reliability than ever previously possible. The creator of the first temporal artery thermometer—the Temporal Scanner™, the most efficacious, non-invasive thermometer ever created. Exergen holds over 100 U.S. and foreign patents, and is the only manufacturer of retail medical thermometers in the U.S. Presently, 30% of hospitals and pediatricians currently use the Exergen Temporal Scanner, and well over 1 million consumers use one at home. Founded by Harvard-research scientist Dr. Francesco Pompei over two decades ago, Exergen Corporation is based in Watertown, Massachusetts, USA.

Fractyl Health is a leader in creating innovative therapies to address the root cause of type 2 diabetes. We were founded based on groundbreaking research and biological insights showing the key role of the intestine in metabolic control. Our therapies are uniquely designed to target and control this controller for the treatment of metabolic disease. Our lead program, Revita DMR, is a first-in-class procedural therapy that is now in late-stage clinical trials for the treatment of type 2 diabetes. Our team is made up of passionate innovators at the intersection of biology and technology, working to deliver better real-world outcomes for people with metabolic disease.

Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions. Through its industry-leading network of dialysis facilities and outpatient cardiac and vascular labs, Fresenius Medical Care North America provides coordinated healthcare services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent. As the world's largest fully integrated renal company, it offers specialty pharmacy and laboratory services, and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products, and renal pharmaceuticals. For more information, visit the FMCNA website at https://fmcna.com/.

Freudenberg Medical is a global partner for the design, development and manufacture of medical devices, components, and minimally invasive product solutions. Our comprehensive technical capabilities range from the design and manufacture of minimally invasive, catheter, and handheld technology to the development and production of medical components utilizing advanced materials and processes. We are an industry leader in the manufacture of high precision silicone and thermoplastic components and tubing as well as metal hypotubes and coating technology. Freudenberg Medical is part of the Freudenberg Group, a global technology group. As an organization, we ensure that every project is supported by our unmatched range of global resources, financial stability, and the flexibility to optimize for business performance. www.FreudenbergMedical.com Explore the possibilities with Freudenberg Medical, please call 877-308-0558 or email info@freudenbergmedical.com

Freyja’s mission is to raise the standard of women’s health in both surgical and in-office procedures, enabling physicians to deliver safe and effective care.

Glytec's industry leading SaaS platform, trusted by 350+ hospitals, empowers collaborative diabetes management and insulin dosing, improving patient outcomes, reducing readmissions, and streamlining workflows while delivering a 6-8x ROI. The first-ever FDA-cleared cloud-based insulin management software is EMR-integrated, easy to set up, and validated by 106 patents and over 100 publications. The Glytec Glucommander® solution, with clinical decision support, workflow alerts, patient monitoring, at-risk patient identification, and AI-driven analytics, is supported by a mission-driven team dedicated to helping healthcare leaders, clinicians and patients promote health equity and improve diabetes outcomes from hospital to home. We are on a mission, join us. For more information, follow Glytec on X (@Glytec) or visit www.Glytec.com.

General Prognostics (GPx) is revolutionizing remote chronic disease management with the world's first bloodless blood tests. Headquartered in Boston, MA, GPx is dedicated to transforming the standard of care of cardiorenal diseases and enabling patients to better understand their condition, much like the continuous glucose monitor has transformed diabetes care.

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. We sell our products to thousands of researchers in over 100 countries through our full-line catalog (and various other specialty catalogs), our websites, and through distributors, including GE Healthcare, Thermo Fisher Scientific Inc., and VWR. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, and Spain and sales facilities in France and Canada.

HEMEDEX INC. was founded in 2000 to commercialize a proprietary platform technology conceived at the Massachusetts Institute of Technology (MIT) to quantify tissue perfusion (i.e., blood flow at the capillary level). This technology addresses the need for real-time, prognostic data in complex medical and surgical procedures. These complex procedures often involve compromised vasculature, delayed ischemia, or other serious pathophysiology, resulting in high rates of morbidity, delayed recuperation, poor patient outcome and higher overall costs. HEMEDEX's patented technology can provide an early warning of impending tissue ischemia, help target appropriate therapies, and rapidly assess the effect of interventions on cerebral blood flow (CBF), thus providing clinicians with a powerful tool to enhance patient care. HEMEDEX is ISO 13485:2012 certified.

Hyalex Orthopaedics is a venture backed Boston-based medical device start-up focused on developing and commercializing new products that feature HYALEX® materials technology. Unlike other polymers, synthetic HYALEX material has the unique capability of maintaining low friction and low wear under the high loads encountered in human joints. Hyalex Orthopaedics' products are in the development stage and have not been approved for use in humans by any regulatory agency.

InfoBionic.Ai's MoMe® ARC system empowers physicians with control to transform the efficiency with which they manage cardiac arrhythmia detection and monitoring processes for their patients. Leveraging a comprehensive, Cloud-based remote patient monitoring platform – the first and only of its kind – we deliver on-demand, actionable monitoring data and analytics directly to the physicians themselves. The MoMe® Kardia 3-in-1 device streams continuous ECG, respiration, and motion data to the Cloud for analysis, and delivers automated reporting to an iPad and or a web-based portal where physicians can access and interact with the data they need, in the detail they want – anytime, anywhere.

There are still broad swaths of uncharted territories concerning the role lipid core plaques play in heart disease. Now, you can achieve unparalleled insights with the Infraredx Dualpro IVUS+NIRS catheter and its accompanying Makoto Intravascular Imaging System, FDA-cleared to identify patients and plaques at an increased risk of MACE. For more information about the Makoto Imaging System or Dualpro IVUS+NIRS Catheter visit www.infraredx.com. Infraredx, a Nipro Company is now proud to offer the OKAY II Y-Connector to the US market. The number one selling Y-Connector in Japan is now available. Visit www.infraredx.com/technology/nipro-okay-ii/ to learn how you can reduce blood loss with the OKAY II Y-Connector.

InnovHeart, with locations in Milan, Italy, and Boston, Massachusetts, develops transcatheter mitral valve replacement (TMVR) systems to treat patients suffering from mitral valve disease. The company is currently in clinical trials testing its novel TMVR Saturn Prosthesis, designed to be consistent with the anatomy of the mitral valve. Saturn is a low-profile prosthetic designed for both Trans-apical and Trans-septal delivery. Our company mission is to bring patients a novel therapeutic system suitable to replace incompetent Mitral Valves based on a safe, effective, and easy-to-use transcatheter technology. InnovHeart is committed to pursuing this goal with the highest level of quality.

inQB8 is a med-tech incubator founded in 2018 to develop novel, device-based solutions for the biggest cardiovascular challenges and create successful start-ups that can bring those solutions to the patients that need them most.

Insulet Corporation, headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod® Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. Founded in 2000 (NASDAQ: PODD), Insulet operates with a customer-centric focus to supply high-quality products and expand the use of insulin pump therapy. Omnipod products are now available in 20+ countries around the globe. HIRING SCAM ALERT Recently, individuals impersonating Insulet Human Resources members have offered fraudulent interviews and job offers to unsuspecting candidates. To help protect you from these scam artists, please be aware that: • Insulet will never interview a candidate over RingCentral, similar messaging apps or social media (i.e. Google Hangouts, WhatsApp, Facebook Messenger, etc.), or via text message. • Insulet will never send a company check or ask an applicant to pay a fee or purchase at home work/training materials in connection with an application for employment. • Insulet will never provide excess money to an applicant and ask the applicant to write a check for repayment. If you have any doubt about a job offer or any other communication purporting to come from Insulet, please reach out to us directly at 978-600-7000. If you receive any type of communication on behalf of Insulet that seems inappropriate or suspicious, please report this activity to: www.iC3.gov or www.stopfraud.gov.

At INVO bioscience, we are democratizing fertility. Our mission is to help people realize the dream of parenthood by increasing worldwide access to an efficient, effective, and connected experience in reproductive treatment. We are the manufacturers of INVOcell. The first and only FDA cleared, CE marked medical device used in intravaginal culture (IVC). INVOcell holds the gametes within the woman’s body during fertilization and early embryo development. A safe, intimate way for women to be connected right from the very beginning. With INVOcell, Life Begins Within™. We are looking for partners to help us bring treatment where it’s needed. We offer full-service partnerships including resources, training, clinical and lab support. Contact us to learn how you can join the movement to make advanced fertility care within reach.

Ivenix is a medical technology company that specializes in the development of large-volume infusion pumps dedicated to eliminating infusion-related patient harm.

Jordi Labs was founded in 1980 to provide the highest quality analytical services, polymer based HPLC columns and packing media in the industry. As a family company, we take pride in the production of each of our products. Customers in nearly all industries are currently using our columns, packing media, and SPE products worldwide. It is our goal to help our customers overcome their analytical challenges by providing excellent products and personal assistance from our highly trained staff. Jordi Labs provides contract analytical services with a special emphasis on chemical identification and liquid chromatography products. Products We manufacture a complete line of polymer-based high-pressure liquid chromatographic (HPLC) columns and gels for all types of applications including size exclusion (SEC) and solid phase extraction (SPE) cartridges. Analytical Service The service laboratory at Jordi provides extensive and specialized analytical testing of polymers, additives and other small molecules. Typical projects include product failure analysis, HPLC method development, polymer filler and additive quantitation, and unknown identification. Other services include method development, prep HPLC, training, depositions and consulting. Our two-fold business of providing services, as well as products, is especially qualified to meet the demands of the polymer industry.

Latham BioPharm Group (LBG), part of Sia Partners, is a leading life sciences consulting company that works with pharmaceutical, biotech, CROs, academia, and medical device/diagnostic companies to solve complex business, regulatory, and product development challenges. Our experienced consultants come from large pharmaceutical companies, small biotechs, academia, and global CROs/CDMOs, and many have even held senior positions with government agencies. Since our founding in 1996, we have grown steadily and have built a robust capability set that has enabled us to help life sciences companies of various sizes drive long-term value into their organizations. In 2022, we became part of Sia Partners when they launched a division dedicated to life sciences consulting—a mutually beneficial merger that will open new doors as we look towards the future. Our core services include: • Product Development • Non-dilutive Funding • Strategic Consulting We are guided by value, both in our business model and in our industry-leading consulting. Our approach is scalable, flexible, and client-centric. We regard you as a partner and become a trusted part of your team. We adapt to your processes and align with your strategic direction and company objectives to generate meaningful analysis and quantifiable results. Both global organizations and emerging start-ups rely on us to guide their products and portfolios down a clear path to success. Sia Partners Sia Partners is a next-generation management consulting firm and pioneer of Consulting 4.0. We offer a unique blend of AI and design capabilities, augmenting traditional consulting to deliver superior value to our clients. With expertise in more than 30 sectors and services, we optimize client projects worldwide. Through our Consulting for Good approach, we strive for next-level impact by developing innovative CSR solutions for our clients, making sustainability a lever for profitable transformation.

LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. The company is listed on NASDAQ.

Leuko is developing the first non-invasive white blood cell device. White blood cell assessment is a first-line indicator for various medically-relevant situations, ranging from chemotherapy management to the detection of life threatening infections worldwide. This test is currently invasive and not readily accessible - it requires patient travel, blood draws and laboratory infrastructure. Based on MIT research, Leuko is re-imagining the way to perform these tests without extracting blood and in a portable device.

Magellan Diagnostics is a medical device company that provides point-of-care systems, clinical laboratory instruments, and analytical laboratory services focused on lead testing.

Developer of bio-engineered surgical implants designed to facilitate new tissue growth and also aid in connective tissue repair. The company's implants specialize in viable alternatives to conventional ACL reconstruction for patients who have sustained any kind of leg injury, enabling surgeons to perform surgery to restore normal anatomy and function of the knee.

myBiometry is a platform to remotely monitor and manage patients with chronic conditions using software and biomarker data generated from proprietary sensors. Our initial focus is asthma.

Myolex is disrupting how to measure muscle wasting (and treatment), caused by obesity drugs, aging, and sport injuries. Myolex® EIM is a patented device technology and SaaS data analytics platform that is built to disrupt skeletal muscle measurement by becoming the clinical and wellness standard to aid in the diagnosis and treatment of obesity drug and age-related muscle wasting. Myolex has developed the 1st quantitative, sensitive, painless, portable for home use muscle quality assessment device that is specifically designed to non-invasively, comprehensibly, and precisely detect and monitor single muscle wasting.

Myomo is a healthcare technology company that specializes in assistive technology for rehabilitation and mobility solutions.

Nanofuse is a regenerative therapeutic that has the properties of replacing or "regenerating" human bone cells to form normal bone. NanoFUSE Biologics products contain the only bioactive glass that is FDA-Cleared to be combined with demineralized bone matrix (DBM). The regenerative efficacy comes from the osteoinductivity of the DBM component plus the osteopromotivity of the bioactive glass. Bioactive glass has been clinically proven for over 30 years but only until now has NanoFUSE Biologics used bioactive glass to create a revolutionary and patented regenerative therapeutic.

NanoHive Medical (formerly HD LifeSciences) created the proprietary, biomimetic Soft Titanium technology, which clearly distinguishes their products in the $1.9B spinal interbody fusion device market. The Hive™ portfolio of interbody fusion devices provides surgeons and their patients with the ideal features that lead to consistently strong fusion constructs and efficacious clinical experiences.

Navigation Sciences™ is a clinical-stage company developing the NaviSci™ System for the tissue conserving removal of lung cancer and other soft tissue tumors. The system integrates Augmented Reality (AR) and advanced software with surgical instruments to guide precise surgical resection by enabling for the first time, real-time in-vivo margin measurement. The system aims to improve surgical outcomes with cutting-edge technologies that – reduce recurrence risk and conserve lung function – shorten hospital length of stay and enhance surgical workflow.

NeuroBionics is pioneering the future of precision bioelectronic medicine by developing the next generation of implantable devices, designed to seamlessly interface with the human body. Our core technology lies in flexible, multifunctional fibers the size of a human hair, which can record and stimulate neural activity, deliver drugs, and ablate tissue. Using an endovascular approach, we will navigate our microscopic-sized flexible fiber implant through the intricate network of blood vessels to deliver precise therapeutic intervention to neural tissue. By making neural interfacing a minimally-invasive procedure, we will revolutionize deep brain stimulation and broaden access to this lifechanging therapy. By doing so, we aim to improve the lives of millions grappling with conditions like Parkinson's disease, essential tremor, epilepsy, and depression.

Neutron Therapeutics LLC is a pioneer in Boron Neutron Capture Therapy (BNCT) using our nuBeam platform, the world's only neutron beam for BNCT that conforms to IAEA international standard for clinical use.

Nova Biomedical is a company dedicated to using advanced technology to develop better blood testing analyzers for medical use. These products are called in vitro diagnostic devices (IVD). We use some of the same advanced technology to provide the biotechnology industry with innovative instruments for cell culture monitoring. Nova is the largest privately owned IVD company in the U.S. and the third largest in the world, with over 1,200 employees globally. Our eight percent compounded annual growth over nearly a decade is more than double the IVD market growth, making Nova one the fastest growing IVD companies in the world. Corporate Commitment to Quality Nova's size and rapid growth are the result of customers throughout the world responding to the exceptional quality and value of Nova's technology, products, and customer service. Our strong corporate commitment to these three areas has made Nova a world leader in clinical, veterinary, and biotechnology chemistry testing analyzers. A Leader in Medical Science Technology Maintaining leadership in any technology industry requires a long-term perspective and commitment to research and development. Nova Biomedical has consistently invested more than 10 percent of sales into research and development — more than double the industry average. Our investment in research and development provides a continuous product pipeline of new and better technology products for our customers. Working at Nova Biomedical We practice our core values of mutual respect, honesty, and integrity throughout Nova. With a strong sense of family in the workplace, we are proud that one third of all our employees have been with us for over 10 years.

NxStage is more than just a company; we are leading the renal revolution. By our own design, we’re at the leading edge of a movement to transform renal care. To make it simpler. To make it portable. To expand treatment options for clinicians by overcoming traditional barriers. To enhance patient freedom and fulfillment. With significant breakthroughs already behind us - and others in the pipeline - NxStage is finding itself at the forefront of dramatically improved renal care, thanks to innovative yet simple therapeutic solutions that benefit patients, caregivers, and society. Our approach – and success is inspiring patients and providers.

Ora is the world's leading full-service ophthalmic drug and device development firm with offices in the United States, United Kingdom, Australia, and Asia. For over 45 years, we have proudly helped our clients earn more than 85 product approvals. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market. Ora's pre-clinical and clinical models, unique methodologies, integrated clinical data solutions, and global regulatory strategies have been refined and proven across thousands of global projects. We bring together the world's most extensive and experienced team of ophthalmic experts, R&D professionals, and management executives to maximize the value of new product initiatives.

Organogenesis™ is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care.

Ossio is an orthopedic medical device company founded in Israel in 2014 with the vision to completely transform the orthopedic experience for physicians, patients, and payors. Ossio's mission is to replace metal implants as the standard of care in the $10B+ orthopedic fixation market (screws, pins, plates) with an intelligent bone regeneration technology. OSSIOfiber™ represents a breakthrough material platform for orthopedic and podiatric surgeons who seek a more biologically friendly way to restore mobility with nothing permanent left behind. Our products have the mechanical strength needed for easy insertion and secure fixation while enabling the body to regrow bone, completely incorporating and replacing the implant without the adverse inflammation and weakness often seen in “bio-resorbables”.

PathMaker Neurosystems is a near-commercial stage neuromodulation company founded to commercialize recent advances in the development of non-invasive devices for the treatment of patients with serious neurological conditions. The company's technology is based on the premise that electrical fields can be used to stimulate the nervous system in a non-invasive manner, offering the potential to treat a wide range of neurological disorders.

PharmaLex is now part of Cencora, a leading global pharmaceutical solutions organization centered on improving lives around the world PharmaLex adds to Cencora's expanding suite of pharma solutions and serves the pharma, biotech, and medtech industries. We guide clients from early strategic planning activities and non-clinical requirements through clinical development, regulatory submission processes and post-approval / maintenance post-launch activities. Our experts use technology-elevated solutions to support clients through the entire product lifecycle. Learn more at http://www.pharmalex.com

Podimetrics is the creator of the SmartMat™ and integrated clinical and patient support services that can help save the limbs and lives of patients living with complex diabetes. We provide high-risk patients our SmartMat™ through partnerships with payers and at-risk providers, including the Veterans Health Administration. After placing their feet on the mat for just 20 seconds a day, patients’ data are automatically sent to our care management team, which helps address any concerning findings. By combining cutting-edge technology with best-in-class care management, Podimetrics earns high engagement rates from patients and allows clinicians to achieve unparalleled outcomes — keeping vulnerable patients healthy at home and saving limbs, lives, and money. Founded in 2011 by a physician and engineers from MIT and Harvard, Podimetrics is headquartered in Somerville, M.A., and backed by Norwich Ventures, Scientific Health Development, Polaris Partners, and Rock Health. For more information, go to www.podimetrics.com or follow us on Twitter @podimetrics.

Quris-AI is an artificial intelligence innovator that is disrupting drug development. Its machine-learning bio-platform better predicts which drug candidates will safely work in humans, avoiding tremendous costs of failed clinical trials. Quris-AI is led by a track-record team of top scientists and strategic investors. Its first AI-based drug is now prepping for clinical testing.

Collaborative robots have reshaped automation by enabling a wide spectrum of new applications in different industries – but a significant dexterity gap still remains even with these robots. Manipulation of delicate, fragile, or brittle items is still out of reach for robots. Inspired by our human fingertips which provide unmatched dexterity, we have set out to reduce this gap by adding tactile sensing similar to the sensing in our fingertips to enable robotic manipulation of more delicate items. Introducing the Tactile Fingertip. Ras labs has combined material science innovation with data science and precision engineering to provide the first state of the art, Tactile Fingertip for robotic gripper fingers. Our sensor is based on our patented Electroactive Polymer which can be fabricated in many configurations. Both squishy and a level of firmness. Think our revolutionary technology could help your business? Send us a message. We'd love to chat!

Regel’s technology utilizes a deactivated Cas system (dCas) which targets the epigenome without editing or damaging the DNA. This approach harnesses the natural mechanisms of gene regulation, allowing for efficient and permanent restoration of normal gene expression.

Reprieve Cardiovascular, Inc. is developing innovative and groundbreaking therapies that aim to improve the lives of more than 25 million heart failure patients around the world. Reprieve is bringing intelligence to decongestion management to safely accelerate fluid removal for heart failure patients. In 2022, Reprieve initiated the FASTR Trial (pilot study) to compare decongestive therapy administered by the Reprieve Decongestion Management System to Optimal Diuretic Therapy in the treatment of patients diagnosed with acute decompensated heart failure. Reprieve is a privately held medical device company, headquartered in Milford, Massachusetts, USA.

Rapid Reliable Results COVID testing has shined a light on a major bottleneck in the laboratory workflow for accessioning samples, decapping of the samples, and movement of the samples into high throughput assay workflows. Rhinostics offers a simple and elegant solution that can remove time and significant labor, allowing laboratories to move larger number of samples through their laboratories at a lower cost, lower error rates, and with time savings. Rhinostics is revolutionizing sample collection with comfortable, automatable, rapid solutions that concentrate samples that save time, costs, and improve assay sensitivity. The polypropylene anterior nares (nostril) collection device is comfortable and easy for self-collection or in the clinic. It is connected to a threaded cap that can be automatically decapped using the Hamilton Lab Elite instrument. The samples can be shipped dry (RT-PCR does not require live virus so viral transport media (VTM) is not required. The entire 96 well plate of vials can be simultaneously scanned through a 2D barcode on the bottom of the collection vial and the automated decapper robot can be connected to other liquid handling systems and linked into the high throughput assay workflow.

Riparian Pharmaceuticals is an early stage biotechnology company employing innovative models of vascular pathophysiology to discover novel therapeutics In nature, the riparian zone is a unique rich ecosystem created through the interaction of a river with its banks. In the human body, moving blood, or hemodynamics, similarly interacts with the walls of blood vessels generating unique biological activity. This very interaction, between hemodynamics and the vascular wall, is a critical and unexplored determinant of vascular health. Riparian is deploying hemodynamics as a tool to discover first in class therapeutics acting on new pathways at an earlier stage of disease than is possible today.

Signifier Medical Technologies Ltd is a medical technology company based in London, UK, with a U.S. office in Needham, Massachusetts. Founded in 2015, the company specializes in non-invasive solutions for sleep-disordered breathing conditions, particularly snoring and sleep apnea. Its mission is to enhance population health and lower healthcare costs through innovative therapies that focus on daytime treatments, avoiding surgical implants or wearable devices during sleep. The flagship product, eXciteOSA®, is an FDA-cleared device designed for mild obstructive sleep apnea and snoring. It employs neuromuscular electrical stimulation to strengthen tongue muscles, helping to reduce airway collapse during sleep. Signifier Medical Technologies is committed to retraining upper airway muscles as an alternative to traditional CPAP machines and surgical options. The company has established partnerships, including a significant order from Spectrum Sleep Solutions Inc., reflecting its growing presence in clinical channels and sleep therapy providers.

Smith & Nephew plc is a healthcare company that specializes in medical devices for orthopedics, wound care, and surgical equipment.

Solid Biosciences (Solid) is a life science company singularly focused on solving Duchenne muscular dystrophy (Duchenne). We aim to be the center of excellence across the entire disease spectrum, serving as a catalyst to bring together those with the expertise in science, technology, disease management and care. Disease-focused and founded by a family directly impacted, our mandate is simple yet comprehensive - attack the roots of the disease and improve daily life for patients.

SpectraWAVE, located in Bedford, Mass., is a privately held medical device company founded in 2017 to provide unrivaled optical and computational insights to improve the treatment and outcomes for patients with coronary artery disease (CAD). CAD, the buildup of plaque in the wall of the arteries that supply blood to the heart, affects 18.2 million adults age 20 and older. In CAD patients that undergo percutaneous stent placement, it is estimated that one in five patients experience adverse events within two years. SpectraWAVE’s state of the art HyperVue™ Imaging System combines next generation DeepOCT™ images and near infrared spectroscopy (NIRS) with workflows optimized for the cardiac catheterization lab. The HyperVue Imaging System is intended for the imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. The NIRS capability of the system is intended for the identification of patients and plaques at increased risk of major adverse cardiac events. For more information and complete indications for use, please visit www.spectrawave.com.

TellBio Inc. is a development stage biotechnology company with the goal to revolutionize the detection and treatment of cancer through its unique and proprietary circulating tumor cells (CTCs) technology and complementary therapeutics platform,

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Theromics has developed a novel, safe Thermal Accelerant used during the microwave, RFA, or cryoablation procedures of soft tissue, fibroids, and bone HeatSYNC can augment the reach of thermal energy from a distance normally unattainable by microwave or radiofrequency devices, thus high-power energy is not needed. The gel is also being studied for use as a drug delivery system combined with thermal ablation for a new therapy called TACT - Thermally Activated Combination Therapy.

Vesigen is developing groundbreaking therapeutic products directed to intracellular targets using a scalable and extracellular vesicle delivery technology. Our patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), enables us to deliver a wide range of payloads, including RNAs (mRNA, shRNA, ribozymes), proteins (signaling proteins, enzymes, antibody fragments), and editing complexes (Cas9/gRNA) directly into the cytoplasm of target cells, expanding the universe of druggable targets. Our team is committed to leveraging ARMMs technology to enable new therapies and address currently unmet medical needs.

At the Wyss Institute, we leverage recent insights into how Nature builds, controls and manufactures to develop new engineering innovations - a new field of research we call Biologically Inspired Engineering. Our scientists, engineers and clinicians, who come from Harvard's Schools of Medicine, Engineering, Arts & Sciences, Design, and Education as well as 12 collaborating academic institutions and hospitals, work alongside staff with industrial experience in product development to engineer transformative solutions to some of the world’s greatest problems. By emulating biological principles of self assembly, organization and regulation, we are developing disruptive technology solutions for healthcare, energy, architecture, robotics, and manufacturing, which are translated into commercial products and therapies through formation of new startups and corporate alliances.

Xontogeny (zon-TOJ-uh-nee) is a biotech aggregator with a differentiated business model to support the accelerated development of life science technologies in the pursuit of helping patients with serious diseases. Specifically, we partner with entrepreneurs, providing the leadership and operating experience needed to increase the probability of success with early drug and technology development. At Xontogeny, we believe that scientific founders supply the passion and determination integral to the success of their companies. While the foundation of success is good science, how that science is developed from inception to maturity serves as the critical pathway. Therefore, we focus on supporting the entrepreneur's pursuit and optimizing the development pathway with an exceptionally talented and experienced operational team. With our team's track record of success, entrepreneurs of affiliated companies will gain the support and guidance they need while remaining lean, virtual, and without the financial burden of supporting a full-time team. This dynamic model has the additional benefit of supporting the goals of the founding scientists and entrepreneurs to retain more control and equity, while increasing the chance of accessing investment, and ultimately development success.

ZSFab dedicates to produce high performance, low-cost, customized medical implants, surgical guides and anatomical models. We are developing unique solutions that integrate our own software tools, advanced modeling and optimization methods, and 3D printing technology. Each of us is born unique, and such uniqueness is imprinted in our DNA and reflected in our finger print, our face, our bone. Such uniqueness requires that when the part is worn, damaged, or aged, the replacement shall be the same. With the help of additive manufacturing, ZSFab is to structure, design, print the best medical implants and assist in the healing process. ZSFab has the goal to provide the solutions for health care, including surgical process. With the products of ZSFab, we will help to ease the burden of the doctors and release our customers of prolonged pain. In ZSFab, we believe: all men are created equal, but shall be treated differently, when it comes to healthcare.